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Sphingolipids. A significant corpus of work over the last decade cated in many of the most critical and fundamental as-
has firmly established an important role for sphingolipids in a pects of cellular biology, including growth, differentia-
variety of important biological processes. Such processes in- tion, apoptosis, and oncogenesis. On the other hand,clude signaling events related to cell growth, differentiation,
many investigators have been skeptical that there existsprogrammed cell death, and stress responses. These processes
any significant role for sphingolipids in several of thesenot only involve those sphingolipids that accumulate as a result
of a variety of inherited lysosomal storage disorders, but, in critical processes, suggesting that proof of concept re-
addition, sphingolipids associated with long-chain base metab- mains to be established.
olism. This article reviews the chemical properties, pathways, The kidney has historically served as an importantregulated metabolism, and signaling function of sphingolipids.
tissue for the study of sphingolipids. Many glycosphingo-In addition, the potential roles of sphingolipids in renal-specific
lipids are uniquely expressed in renal tissue. Renal epi-processes are considered. While a variety of cellular functions
have been ascribed to sphingolipids, in many cases proof of thelia also serves as a paradigm for the elucidation of
the concept has yet to be well established. Thus, a number of many of the proposed cellular functions of sphingolipids.
critical questions can be posed in interpreting these studies. More recently, sphingolipids have received the attentionSeveral of these questions are considered.
of the renal academic community, serving as the subject
for a growing number of studies in renal physiology and
pathophysiology. It is therefore timely to consider howThe identification of cellular lipids as signaling mole-
recent advances in sphingolipid studies may impact oncules was first suggested almost one half of a century
our understanding of renal physiology, cell biology, andago when it was observed that amylase secretion was
pathophysiology.closely related to the phospholipid content of pigeon
I have previously reviewed the renal biochemistry andpancreas [1]. In subsequent years, several cellular phos-
signaling function of sphingolipids [2, 3]. In the presentpholipids have been identified as substrates for the gen-
review, emerging concepts in these areas are highlighted,eration of signaling molecules, including phophatidylino-
and areas in which proof of concept has not been fullysitol 4,5-bisphosphate and phosphatidylcholine. The
established are emphasized. However, significant em-identification of sphingomyelin as a substrate for the
phasis is also placed on how these concepts may help usgeneration of receptor-elicited signaling molecules is a
to better understand those processes that have histori-more recent occurrence. Only since 1989 have investiga-
cally been viewed as sphingolipid dependent and thosetors seriously pursued the concept of sphingolipids as
processes that we may wish to re-evaluate in the contextpotentially important cell-signaling mediators. As a re-
of recent advances in sphingolipid biology.sult, the number of published studies in sphingolipid
biology has grown exponentially in the last 10 years.
The corpus of work in the cell biology of sphingolipids CHEMICAL PROPERTIES
has, on the one hand, been met with considerable excite-
Significant work has been focused on understandingment. Not only ceramide, but a variety of additional
the chemical features of sphingolipids based on the beliefsphingolipids are now argued to have second-messenger
that the functional biochemistry of these compounds canfunction. Additionally, sphingolipids have been impli-
be better understood. Sphingolipids are, by definition,
those compounds that contain a long-chain sphingoid
base. The most common long-chain bases are C-18 andKey words: lipids, cell signaling, renal physiology, apoptosis, oncogene-
sis, epithelia. C-20 sphingosines [4]. These bases contain a C4-C5 dou-
ble bond in the trans D-erythro conformation. C-18 andReceived for publication November 17, 1999
C-20 sphinganines (dihydrosphingosines) are the nextand in revised form February 9, 2000
Accepted for publication February 21, 2000 most common long-chain bases. These lack the double
bond.Ó 2000 by the International Society of Nephrology
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When a fatty acid is linked to the amide group of golipids. Factors that further promote clustering include
the content of sialic acid [11], the presence of Ca21 ionsthe long-chain base, the resultant lipid is referred to as
ceramide. The fatty acids vary in composition, but they [12], the ceramide content [13], and proteins such as
VIP21 (caveolin) [14]. The theoretical ability of sphingo-are typically long. The most common fatty acids are
palmitic (C16:0) and stearic (C18:0). a-Hydoxylated fatty lipids to create distinct microenvironments within the cell
membrane has led investigators to focus on these sitesacids are often present as well.
The primary alcoholic function at carbon one of cera- as “hot spots” for transmembrane signaling sites, as well
as sites of vesciculation and membrane transport [15].mide is the site of attachment for a variety of additional
moieties. These most commonly include phosphocho- Several acronyms have been applied to these theoreti-
cal membrane domains. These include “detergent-resistantline-producing sphingomyelins and saccharides produc-
ing a multitude of glycosphingolipids. When a single mo- membranes,” “detergent insoluble glycolipid-enriched
membrane domains,” and “lipid rafts” [16]. Small tubo-nosaccharide is present (glucose or galactose), the lipid
is referred to as a cerebroside. There may be as many as vesicular invaginations within the plasma membrane,
termed caveolae, are included within detergent-resistant15 to 20 sugars in the oligosaccharide chain. When these
sugars are uncharged, the products are referred to as neu- fractions. In addition, density gradient methods can be
used to isolate caveolin-containing membrane fractionstral glycosphingolipids. Acidic glycosphingolipids result
when one or more sialic acids are present (gangliosides) that are enriched in glycosphingolipids [17]. On the other
hand, glycosphingolipid-enriched fractions can be iso-or when a sulfate group is present (sulfatides) [5]. Less
commonly, a phosphate may be placed at the C-1 carbon- lated from cells not containing caveolin or having mor-
phologic evidence of caveolae [18].producing ceramide-1-phosphate [6]. Recently, it has been
shown that an additional acyl group may be present at Some investigators have argued, however, that such
domains are unlikely to be present. The interactionsthe C-1 position as well producing 1-O-acylceramide [7].
The ceramide portion of a sphingolipid is highly hy- required to form lateral domains between lipid species
drophobic. When a polar head group is present, such as are not sufficiently strong or long lived to be biologically
a phosphorylcholine or oligosaccharide, the sphingolipid significant [19]. In addition, the energy required to demix
becomes amphipathic in character. The presence of the lipid species once aggregated into domains is small.
phosphorylcholine head group on both phospatidylcho- While microscopy-based experimental evidence exists in
line and sphingomyelin would lead one to conjecture support of such lipid rafts, a number of critical questions
that physicochemical properties are similar because of need to be addressed to provide a more cogent model
a similar molecular conformation. However, there are of their biological significance [20]. These questions in-
pronounced differences between the two lipids. First, clude a determination of the size, composition, and dy-
differences in the number of methylene groups (para- namics of these structures, as well as the relationship of
finnic tail length) are more pronounced between the such rafts to the cytoskeleton and understanding how
long-chain base and fatty acids in ceramide than in the the outer membrane leaflet that is enriched in putative
diglyceride function of phosphatidylcholine. These para- raft components (glycosphingolipids, cholesterol, sphin-
finnic tails are believed to interdigitate with like mole- gomyelin, and GPI-linked proteins) interacts with the
cules on either side of the lipid bilayer [8]. In addition, inner leaflet of the membrane.
the interfacial region at the juncture of the lipid bilayer
and the polar head group of sphingomyelin is believed
SPHINGOLIPID PATHWAYSto be more polar than the comparable region in phospha-
De novo formation of long-chain sphingoid bases be-tidylcholine. This creates more potential sites of interac-
gins with the condensation of palmitoyl-CoA and serine,tion between water and other compartments of the lipid
forming 3-ketodihydrosphingosine (Fig. 1) [21]. This pyr-bilayer, including the phosphate, free hydroxyl at C-3,
idoxal 59-phosphate–dependent enzyme demonstratesand the trans double bond at C4 and C5 [9]. The conse-
distinct specificities for various acyl-CoAs, with palmi-quences of these chemical interactions include a higher
toyl-CoA preferred over stearoyl-CoA by a ratio of 5:1melting point, increased microviscosity, enhanced stabil-
[22]. This specificity is reflected in the relative abundanceity, and decreased permeability to electrolytes than is ob-
of 18 and 20 carbon long-chain bases found in mamma-served with glycerolipids of homologous structures [10].
lian sphingolipids. The reduction to sphinganine (dihy-The compositional diversity of membrane lipids is
drosphingosine) is then catalyzed by an oxidoreductase,thought to facilitate a lateral phase separation of differ-
which is NADPH dependent [23]. Dihydroceramide (N-ent lipid components. In the case of sphingolipids, the
acylsphinganine) is formed by an acylation reaction thatdecrement in membrane fluidity may cause microdo-
uses acyl-CoAs as substrates. The enzyme catalyzing themains or clusters of lipids rich in ceramide to form. This
acylation of sphinganine is acyl-CoA:sphingoid base N-separation may be facilitated by the composition of the
polar head groups on both neutral and acidic glycosphin- acyltransferase. This enzyme is probably present in many
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Fig. 1. Long-chain base synthesis resulting in
ceramide formation.
different forms, differing in substrate preference and enzyme that acylates dihydrosphinganine has not been
established. There does not appear to exist alternativetissue distribution. The fatty acyl-CoA preference as
characterized to date is stearoyl-CoA . lignoceryl- routes of de novo sphingosine synthesis other than via
the acylation of sphinganine, unsaturation of dihydrocer-CoA . palmitoyl-CoA . oleyl-CoA [24].
Ceramide is formed through the de novo synthetic amide, and deacylation of ceramide by one of several
ceramidases. However, long-chain base acylation may,route by the unsaturation at the 4,5 positions of the
sphingoid amine by another oxidoreductase [25]. This in theory, occur through two alternative routes. First,
an acyl-CoA independent, ATP-dependent mechanismreaction is nicotinamide adenine dinucleotide (NAD)
dependent. Ceramide may alternatively be synthesized may occur through the reversal of ceramidase [26]. Sec-
ond, platelet-activating factor may serve as the substrateby the acylation of sphingosine by an acyl-CoA:sphin-
goid base N-acyltransferase. Whether this is the same for N-acetylation [27].
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Fig. 2. Alternative pathways for ceramide metabolism.
Ceramide is a key intermediate in the formation of gomyelin is thought to synthesized by the transfer of
phosphocholine from phosphatidylcholine to ceramidemost of the biologically important sphingolipids (Fig. 2).
Aside from its deacylation to form free sphingosine, [29]. The responsible enzyme is sphingomyelin synthase.
This enzyme has been localized to the cis and medialthese products use the C1 hydroxyl group on ceramide
as the site for additional groups. These products include Golgi membranes [30]. However, a second enzyme with
similar activity has been detected in the plasma mem-sphingomyelin, cerebrosides and other glycosphingo-
lipids, ceramide-1-phosphate, ceramide-phosphoethano- brane [31]. Because the sphingomyelin synthase pathway
may regulate levels of the precursor ceramide and of alamine, and 1-O-acylceramide.
Sphingomyelin was originally proposed by Sribney product, diacylglycerol, the regulation of these sphingo-
myelin synthases and sites of action may have importantand Kennedy to be formed by the transfer of CDP-
choline to ceramide [28]. This pathway has not been implications for cell-signaling phenomena, as detailed
later in this article.subsequently confirmed. Instead, the majority of sphin-
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Two additional pathways for sphingomyelin synthesis kinase phosphorylates the C-1 position of either sphingo-
sine or sphinganine. It has been characterized as both amay exist. First, a two-step pathway involving the forma-
tion of ceramide phosphoethanolamine followed by its cytosolic enzyme and as membrane bound.
The terminal catabolism of sphingosine involves themethylation has been described [32]. This appears to be
a relatively minor pathway. Second, lyso-sphingomyelin action of sphingosine-1-phosphate lyase, which degrades
sphingosine-1-phosphate to form ethanolamine phos-(sphingosylphosphorylcholine) may be acylated directly
[33]. Sphingosylphosphorylcholine has been demon- phate and a fatty aldehdye. C-18 sphingosine is degraded
to trans-2-hexadecenal, and C-18 sphinganine is de-strated to have cellular actions akin to sphingosine-1-
phosphate [34]. However, there is limited evidence in graded to palmitaldehdye [43]. Alternatively, sphingo-
sine-1-phosphate may be dephosphorylated by the cera-support of the existence of this lysolipid in mammalian
cells. Recently, a bacterial N-deacylase with activity mide-1-phosphate phosphatase [44].
Another pathway for sphingosine metabolism is N-against sphingomyelin has been reported [35]. A compa-
rable activity in mammalian tissues has not been identi- methylation by sphingosine N-methyltransferase [45].
Both monomethyl and dimethyl sphingosines may befied.
Glucosylceramide is formed from ceramide and UDP- formed by this pathway.
glucose by UDP-glucose:ceramide glycosyltransferase
[36]. Glucosylceramide is the precursor for most of the
REGULATION OF METABOLISM
mammalian glycosphingolipids. The reaction occurs on
The subcellular sites of metabolism and the subcellularthe cytoplasmic side of the cis Golgi [37]. Subsequent
distribution of sphingolipids are important determinantsglycosylation steps occur within the luminal side of the
in understanding the cellular biology of these lipids. Thecis Golgi. How ceramide is translocated from the endo-
role of various sphingolipids in cell-signaling events hasplasmic reticulum to the Golgi and how glucosylceramide
been difficult at times to reconcile with some of theis flipped into the luminal side of the Golgi is unknown.
known properties and with the subcellular localization ofGlucosylceramide can then be further glycosylated
the relevant enzymes. In addition, it is unknown whetherwithin the Golgi or can be directly transported to the plas-
many of these enzymes that colocalize to specific cellularma membrane. The latter pathway may occur through
organelles are present in multienzyme complexes.the action of a glycolipid transfer protein.
In general, all of the enzymes associated with de novoCeramide may also undergo phosphorylation at the
long-chain base synthesis and ceramide formation areC-1 position, forming ceramide-1-phosphate [38]. This
present in the smooth endoplasmic reticulum [46]. Fur-pathway is catalyzed by a distinct calcium-dependent
thermore, the active sites for these enzymes appear toceramide kinase. Ceramide-1-phosphate may also be
be on the cytosolic face of the endoplasmic reticulum.formed by the action of bacterial diglyceride kinase [39].
The localization and site of the dihydroceramide oxido-This latter reaction serves as the basis for the analytical
reductase have not been established. Acyl-CoA:sphin-determination of ceramide levels. To date, ceramide ki-
goid base acyltransferase has also been shown to localizenase activity has been identified in synaptic vesicles [6],
to mitochondria [47]. Whether this mitochondrial activ-leukemia cells [39], and neutrophils [40].
ity may have some role in ceramide-induced apoptosisAnother recently described pathway for ceramide
(discussed later in this article) is an intriguing yet unan-involves its acylation at the C-1 position forming 1-O-
swered question.acylceramide. The substrate for this acylation is phospha-
Sphingomyelin biosynthesis appears to occur primar-tidylethanolamine or phosphatidylcholine [7]. This reac-
ily within the cis and medial Golgi membranes, with thetion is catalyzed by a microsomal phospholipase A2 that
active site within the luminal leaflet. This implies thattransacylates the fatty acid [41]. The phospholipase is
de novo synthesized ceramide must be transported fromunique in that it is calcium independent and has an acidic
the endoplamic reticulum to the Golgi. In addition, therepH optimum.
must be a translocation of ceramide across the lipid bi-The main catabolic pathways for sphingolipids in gen-
layer. In addition, a similar enzymatic activity has beeneral and for ceramide in particular appear to be through
identified in the plasma membrane [48]. This latter find-endosomal/lysosomal pathways. Glycosphingolipids are
ing implies that ceramide formed from sphingomyelindegraded via one or more glycosidases, and ceramide is
hydrolysis may be resynthesized at the site of its degrada-degraded by an acidic ceramidase. The latter reaction
tion within the plasma membrane without intracellularresults in the formation of sphingosine and a fatty acid.
transport to the Golgi.Free sphingosine is released from the lysosome by an
The degradation of sphingomyelin is catalyzed byuncharacterized pathway. Free sphingosine is further ca-
a phosphodiesterase-producing phosphorylcholine andtabolized outside of the lysosome. It may be reacylated
ceramide. This sphingomyelinase activity is separableforming ceramide or phosphorylated by sphingosine ki-
nase to form sphingosine phosphate [42]. Sphingosine into at least seven distinct activities. These include (1)
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an acidic, lysosomal sphingomyelinase [49], (2) a zinc- in both its complexity and, at times, inconsistencies. In
some cases, the implication that sphingolipids such asdependent serum sphingomyelinase [50], (3) a neutral,
magnesium-dependent, membrane associate sphingomy- ceramide may play a primary role in cell signaling has
been highly controversial. This has been particularly trueelinase [51], (4) a neutral Mg21-independent sphingo-
myelinase identified in the myelin sheath [52], (5) a for hypotheses stating that ceramide regulates nuclear
factor-kB (NF-kB) signaling and apoptosis [67, 68].magnesium and dithiothreitol-stimulated neutral sphin-
gomyelinase found in the nuclei of ascites cells [53], (6) In general, those agonists that increase cell ceramide
levels cause cell growth arrest, differentiation, or apopto-a neutral sphingomyelinase localized to the chromatin
and nuclear envelop of liver cells [54], and (7) an alkaline sis. These include the cytokines [69], environmental
stressors [70], and pharmacologic agents [71]. The down-sphingomyelinase in the bile and intestine [55].
Many of these sphingomyelinase activities have been stream cellular responses are most often consistent with
these effects and include NF-kB activation [72], cyclo-implicated in cellular sphingolipid-signaling events. Thus,
considerable attention has been focused on the biochem- oxygenase transcription [73], heat-shock protein tran-
scription [74], selectin expression [75], and cytokine se-istry of these lipases in recent years. Structurally, the best
studied of these sphingomyelinases is the acid, lysosomal cretion [76]. Conversely, the growth factors are often
associated with an increase in sphingosine and sphingo-sphingomyelinase [56]. This lipase is deficient in patients
with Niemann-Pick disease, a lysosomal storage disor- sine-1-phosphate [77]. These opposing activities have led
Cuvillier to propose a “yin yang” model of intracellularder. The zinc-dependent serum sphingomyelinase has
been determined to be a product of the same gene [57]. A sphingolipids with ceramide and sphingosine-1-phos-
phate playing opposing roles [78]. In this model, a sphin-neutral, magnesium-dependent, glutathione-stimulated
enzyme has recently been sequenced [58]. Whether this golipid “rheostat” may exist within cells, the setting or
balance of which determines whether cells undergo alipase is a signaling sphingomyelinase is uncertain.
Both sphingomyelin and glycosphingolipids are highly proliferative or differentiation of apoptotic response.
Four primary observations in support of a role forenriched in the outer leaflet of the plasma membrane.
sphingomyelinase-stimulated ceramide formation as aThe mechanism whereby sphingolipids flip from the
transduction event: First, several extracellular stimuliouter to the inner leaflet is unknown. One hypothesis is
trigger ceramide generation and sphingomyelin degrada-that the multidrug resistance protein serves as a mem-
tion. Multiple activators have been associated with thebrane “flipase” for placement of glycosphingolipids such
generation of cellular sphingolipids. An incomplete list-as glucosylceramide in the outer leaflet [59]. It is note-
ing would include cytokines [tumor necrosis factor-aworthy that tumor cells that express high levels of multi-
(TNF-a) [79], interleukin (IL)-1b [80], IL-2 [81], anddrug resistance protein are characterized by high con-
g-interferon [82]], nerve growth factor [83], hormonestents of glucosylceramide [60].
(glucocorticoids [84], progesterone [85], 1,25 (OH)2 vita-
min D3 [86], bradykinin [87], retinoic acid [88], endo-A SIGNALING ROLE FOR SPHINGOLIPIDS thelin 1 [89]), antigens (FAS ligand [90], anti-CD28 [91]),
Interest in the role of sphingolipids as signaling mole- environmental stressors (ionizing radiation [92], heat
cules began after the discovery that sphingosine could shock [74], ischemia [93], hypoxia [94], peroxide [70]),
act as an inhibitor of protein kinase C [61]. In 1989, pharmacologicals (daunorubicin [95], vincristine [96],
Okazaki, Bell, and Hannun reported the first example Ara-C [97], phorbol esters [98], calcium channel blockers
of agonist-coupled degradation of sphingomyelin [62]. [99], protein kinase C inhibitors [100]), and infective
Since that time, the number of published studies on agents (viruses [101], bacteria [102], and bacterial toxins
sphingolipid-based signaling has increased exponen- [103]).
tially. While the majority of attention has been focused Second, sphingomyelinase activity increases in a kinet-
on ceramide, the product of sphingomyelin hydrolysis, ically consistent manner. The degree of increase in cera-
as the principle sphingolipid mediator of intracellular mide is variably reported, ranging from a 20% increase
signaling events, several sphingolipid metabolites gener- to a 2000% increase [90, 94]. Concurrent measurements
ated both as a result of sphingomyelinase activity and of sphingomyelin and ceramide have been made in many
through de novo synthesis have been implicated in sig- studies. In general, sphingomyelin levels or radiolabeling
naling events. Sphingolipids implicated in signaling decrease over time and at a magnitude that is consistent
events include ceramide [63], sphingosine [64], sphingo- with the appearance of ceramide. Often, the sphingomy-
sine-1-phosphate [65], and ceramide-1-phosphate [66]. elin levels return to control values as the ceramide con-
The primary proposed signaling functions for these tent decreases, implying that the ceramide is recycled to
sphingolipids are outlined in Figure 3. sphingomyelin, presumably via the sphingomyelin syn-
The general picture that has emerged of sphingolipid thase. There is some evidence in support of a membrane-
associated sphingomyelin synthase on the inner leafletsignaling is both exciting in its implications and confusing
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Fig. 3. Some proposed signaling functions of ceramide and its metabolites.
of the plasma membrane. There are three implications potential problems confounding the interpretation of the
experimental data.for this model. First, sphingomyelin hydrolysis, ceramide
formation, and sphingomyelin resynthesis would neces- Short-chain ceramides, usually containing an acetyl
group or C6 or C8 fatty acid at the amide linkage, havesarily occur at this site. Second, the ceramide generated
would act at this site on a local target or be transported been extremely popular in signaling studies. These ana-
logues retain the D-erythro stereospecificity of naturalfrom this site to one where such targets exist. The cera-
mide would then be reutilized, or ceramide synthesized ceramides as well as the critical C4-C5 double bond. In
addition, in early studies, these compounds were be-de novo would serve as substrate for resynthesis. Third,
a significant amount of diacylglycerol, the product of lieved to be relatively inert with regard to cellular metab-
olism. Thus, any biological activities observed with thesesphingomyelin synthesis, would be generated and thus
may have independent biological activity. compounds were interpreted as mimics for the activities
of endogenous ceramides.Not only is the degree of ceramide elevation highly
variable, but the time course for ceramide accumulation Several difficulties exist with this interpretation. First,
these ceramides are quite avidly metabolized by cellsis as well. Four patterns of ceramide accumulation have
been described. These include a rapid increase occurring [114]. Original studies often used analogues radiolabeled
within the fatty acid. The liberation of this fatty acid bywithin a few minutes and declining to baseline within 15
to 20 minutes [104], a gradual increase occurring within a ceramidase would result in a long-chain base, which was
unlabeled and in which the metabolism was thereforean hour and decreasing within two to three hours [105],
a rapid increase with a persistent elevation lasting several impossible to follow. More recent studies have demon-
strated that following the addition of these compounds,hours [76], and a gradual increase occurring after several
hours and persisting for 24 hours or longer [106]. Surpris- both short- and long-chain sphingomyelins and glyco-
sphingolipids are synthesized as well as free sphingosine,ingly, these patterns can be observed with the same ago-
nist (IL-1b) [76, 104–107] and are not associated with long-chain ceramides, and long-chain sphingomyelins.
Another problem is that the concentrations of ceramidesthe degree of rise in ceramide.
A third observation in support of a role for sphingomy- added to cells (typically in the micromolar range) result
in intracellular levels of ceramides that are approxi-elin hydrolysis is that the biological consequences of
sphingomyelin degradation and ceramide generation can mately 100 times those found normally. Additionally, in
some cases, comparable biological effects are observed,often be replicated by maneuvers that augment or inhibit
ceramide levels. These methods include the addition of irrespective of the stereoselectivity of the analogue em-
ployed. Finally, because of distinct physiochemical dif-short chain, cell-permeant ceramides [108], the addition
of bacterial sphingomyelinase [109], the use of inhibitors ferences in these analogues, short-chain ceramides may
destabilize membranes through detergent-like effectsof long-chain base acylation [110], the use of inhibitors
that decrease ceramide utilization through glycosylation that are independent of their endogenous biological ac-
tivities [115].pathways [111], the use of inhibitors of ceramide degra-
dation [112], or the addition of natural long-chain cera- The use of exogenous sphingomyelinase has also been
problematic, because the majority of sphingomyelin ismides [113]. Each of these methods is associated with
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in the outer leaflet of the plasma membrane where it dered some discussion because in other systems sphin-
gomyelin hydrolysis and diacylglycerol formation occurwould be accessible to the bacterial enzyme. However,
the pool of sphingomyelin that is susceptible to agonist- simultaneously, D609 may not be specific for phospholi-
pase C, and protein kinase C activation can, at times,stimulated sphingomyelinase activity is believed to exist
on the inner membrane leaflet [116]. Thus, ceramide abrogate biological effects thought to be secondary to
ceramide generation, such as apoptosis.produced with the bacterial enzyme would be present
at a site that may have little to do with the endogenous Another lipid mediator of sphingomyelinase may be
arachidonic acid, the product of phospholipase A2 [79].signaling mechanisms. It is therefore not surprising that
the use of this approach often does not replicate the In HL60 cells, arachidonate formation precedes sphingo-
myelin hydrolysis. The effect was reproducible by mel-biology under investigation.
Inhibitors of glucosylceramide formation (1-phenyl- litin, an activator of phospholipase A2, and is absent in
a cell line defective in cytosolic phospholipase A2. The2-decanoylamino-3-morpholino-propanol [PDMP] and
1-phenyl-2-palmitoylamino-3-pyrrolidino-propenol [P4]) specificity of this effect for arachidonate remains to be
determined, since other polyunsaturated fatty acids may[117, 118], of ceramide synthase (fumonisin B1) [119], or
ceramidase (IS, 2R)-D-erythro-2-(N-myristoylamino)-1- activate neutral sphingomyelinase. In addition, whether
this effect is specific for the cytosolic phospholipase A2phenyl-propanol [MAPP]) [120] have also found popu-
larity. These are also potentially problematic. The ability or whether other phospholipases may mediate this effect
is unknown.of PDMP and its related homologues to raise ceramide
has recently been found to reside at a second site of Glutathione, a tripeptide, serves a major role in pro-
tecting cells against oxidative stress. Reduced glutathi-action, the inhibition of 1-O-acylceramide synthase [41].
De novo ceramide formation, although operative in one is an antioxidant that is depleted in cell death. Both
reduced and oxidized glutathione have been identifiedsome systems [71], is generally not the basis for ceramide
accumulation. Thus, even if highly specific, this fungal as inhibitors of the neutral magnesium-dependent sphin-
toxin may not alter endogenous ceramide levels. In gen- gomyelinase [127, 128]. Support for a role for glutathione
eral, there is little assurance that, even if ceramide levels in the regulation of ceramide formation is based on ex-
can be manipulated by these agents, the ceramide accu- periments demonstrating that prevention of sphingomy-
mulates at a site within the cell at which it would be elin hydrolysis and apoptosis can be prevented by reple-
most biologically active. This consideration would also tion of intracellular glutathione.
apply for the use of the bacterial sphingomyelinase or The interaction of specific membrane proteins cou-
the cell permeant ceramides. pling receptors that activate sphingomyelinases with the
The fourth and final evidence in support of ceramide lipases has been proposed. One such protein is factor
as an important signaling molecule is that some of the associated with neutral sphingomyelinase (FAN) [129].
same responses can be replicated in yeast systems. Yeasts This is a novel WD (tryptophase-aspartic acid) repeat
have been particularly valuable models for understand- protein suggested to link the neutral sphingomyelinase
ing sphingolipid biology. A signaling role for ceramides with the mitogen-activated protein kinase pathway.
as activators of protein phosphatase 2A [121] and for
their role as mediators of the yeast heat shock response
CELLULAR TARGETS FOR SPHINGOLIPIDS[122] has been garnered from the use of this model. More
Several effectors have been demonstrated for sphin-recently, an important role for sphingosine-1-phosphates
golipid activities. Perhaps the best characterized effectorhas been identified by use of S. cervesiae, first as the
is the set of orphan receptors termed Edg-1, Edg-3, andbasis for the identification of the sphingosine kinase [123]
H218/Edg-5 [130]. These comprise a family of structur-and sphingosine-1-phosphate lyase genes [124], and sec-
ally homologous receptors with high affinity and speci-ond through manipulation of long-chain base phosphate
ficity for sphingosine-1-phosphate. Edg-3 and Edg-5 arelevels within yeast. These latter studies have demon-
44% similar to each other and 50% similar to Edg-1. Asstrated a marked protective effect of these metabolites
seven transmembrane-spanning proteins, these recep-in models of heat shock and nutrient deprivation [125].
tors are G-protein coupled. Two related receptors, Edg-2Several mediators have been implicated in the regula-
and Edg-4, appear to couple to lysophosphatidic acidtion of signaling sphingomyelinases. Diacylglycerol was
[131]. Edg-1 was named as the “endothelial differentia-perhaps the first lipid to be suggested to regulate TNF-
tion gene” and was identified as an early response genea–induced ceramide formation. In this model, the hydro-
in endothelial cell differentiation. These receptors arelysis of phosphatidylcholine was thought to be upstream
ubiquitously expressed in multiple tissues.from an acidic sphingomyelinase [126]. Support for this
Several signaling events are observed following sphin-was based largely on the use of D609, believed at the
gosine-1-phosphate binding to cells. These include thetime to be a specific inhibitor of the phosphatidylcholine-
specific phospholipase C. This observation has engen- activation of mitogen-activated protein kinases [132],
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phospholipase C [133], phospholipase D [134], and po- has been reported to be the kinase suppressor of ras
(KSR) in Drosophila [149]. It is suggested to directlytassium channels [135]. In addition, there is inhibition
of adenylyl cyclase [133] and mobilization of intracellular activate Raf and mitogen-activated protein kinase activa-
tion in response to TNF-a.calcium [136]. Of potential importance is the observation
that both P-cadherin transcription and serum response A third potential effector for ceramide is protein ki-
nase C z [150]. Ceramide has been reported to directlyactivation can be induced with sphingosine-1-phosphate
[137]. The latter response is rho dependent and mediates bind to this protein kinase C. A common feature for all
of these putative targets is the presence of a cysteine-richstress-fiber formation. Several other responses to sphin-
gosine-1-phosphate have been observed, including mito- domain that may constitute a portion of the ceramide-
binding site. Additional suggested ceramide targets in-genesis, inhibition of ceramide-induced apoptosis, inhi-
bition of cell motility, neurite retraction, and platelet clude the CPP32, a caspase 3-like apoptotic protease and
the stress activated/c-jun N-terminal protein kinase.activation.
Recent work has attempted to determine which cellu- Historically, it has been difficult to reconcile the role
of ceramide as an effector with potential sites of forma-lar responses are coupled to which receptor and a sub-
units. At present, it appears that Edg-1 couples to mem- tion in the plasma membrane, cytosol, and acidic lyso-
somal or endosomal compartments. Recently, using abers of the Gi family. Edg-3 and Edg-5 couple to Gi in
addition to Gq and G13 [138]. The diversity of receptors photo-crosslinking to a ceramide analogue, cathepsin D,
an acidic aspartate protease was identified as a potentialand G-protein interactions not only explains the relative
sensitivity of some but not all sphingosine-1-phosphate target of ceramide generated by the acidic sphingomyeli-
nase [151].signaling to inhibitors such as pertussis toxin, but may
clarify the differing cellular responses to this agonist.
Sphingosine-1-phosphate is formed intracellularly and
APOPTOSIS AND SPHINGOLIPID SIGNALING
was originally identified as a putative lipid second mes-
Of the proposed roles for sphingolipids in cell signal-senger. It can mobilize calcium from intracellular stores
ing, none has engendered greater interest and generated[139]. Sphingosine phosphate kinase activity is stimu-
greater controversy than the concept that ceramide is alated by factors such as phorbol ester [140], platelet-
signal for programmed cell death. Two primary observa-derived growth factor [141], and Fc receptor ligation
tions have been critical in the development of this hy-[142]. Inhibition of its activity by N,N-dimethylsphingo-
pothesis. First, agonists that induce apoptosis (for exam-sine inhibits cell growth and promotes apoptosis [143].
ple, TNF-a, irradiation, chemotherapeutic drugs, andThe kinase has been cloned in yeast and mammalian
CD95) activate cellular sphingomyelinases and raise cellcells. There is a high degree of conservation of its primary
ceramide levels [90, 92, 96, 97]. Second, the exogenoussequence between yeast, worms, and mammals. There
addition of cell-permeant ceramides or of bacterialis also a significant degree of similarity with diacylglyc-
sphingomyelinase induces an apoptotic response [152].erol z. The lyase and phosphatases have also been cloned
Under this hypothesis, agonists in the form of cell stres-from yeast. Deletion of these genes by homologous re-
sors or of peptide hormones serve as cell death signals bycombination creates an enhanced resistance to heat
activating one or more sphingomyelinases and increasingshock and nutrient deprivation.
ceramide, which then acts as a critical effector for theSeveral potential cytosolic effectors of ceramide activ-
apoptotic pathway.ity have also been identified. One target is one or more
Under the current model for apoptosis, death recep-cytosolic phosphatases termed “ceramide-activated pro-
tors such as the TNF and CD95 receptors activate deathtein phosphatase” (CAPP) [144]. This enzyme is related
effector domain-containing enzymes termed caspasesto the 2A class of heterotrimeric protein phosphatases.
(“cysteine protease that cleaves after aspartic acid”).Support for this target is observed in yeast in which
Activation is mediated by binding to the cytoplasmicceramide-induced growth arrest can be mitigated in yeast
portions of these receptors through adaptor proteinslacking the PP2A subunits [145]. Protein phosphatase 1
such as TRADD, TRF-2, and FADD. Death receptor-may also be stimulated by ceramide [146].
independent stimuli such as etoposide and irradiationAn important substrate for ceramide-stimulated phos-
induce caspase activation at other sites. “Inducer” cas-phatase activity may be the retinoblastoma protein. Cer-
pases (caspase 8) appear to act upstream of the mito-amide and sphingosine stimulate cellular phosphatase
chondrial release of cytochrome c into the cytosol, whichactivity against Rb protein and induce cell cycle arrest
in association with Apaf-1 and caspase-9 subsequentlyat the G1/S transition [147].
process and activate executioner caspases (for example,A second activity that has been identified as a cera-
caspase-3, -6, and -7).mide effector has been termed ceramide-activated pro-
The challenge for proponents of ceramide as a media-tein kinase (CAP kinase) [148]. This represents a mem-
ber of the family of proline-directed protein kinases. It tor of programmed cell death has been to define the
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sphingolipid signaling events in the context of well-estab- similar strategy has been employed for Fabry disease and
is currently under clinical investigation with promisinglished pathways for apoptosis. Unfortunately, no consis-
tent view for the role or the site of action of ceramide in preliminary results [159]. Recombinant enzyme replace-
ment, however, is an exceptionally expensive pharmaco-either the cell death effector-dependent or -independent
pathways. The published data are inconsistent in this logic modality caused by the small potential market and
significant manufacturing costs. b-Glucosidase currentlyregard. Many of the critical questions surrounding the
properties and biological role of sphingomyelin signaling represents the most expensive drug on the market, with
yearly costs in excess of $200,000.detailed previously in this article impact on the evalua-
tion of the strength of the ceramide hypothesis. These An alternative approach is the use of “substrate deple-
tion,” first proposed by Radin [160]. Here, glycosphingo-questions include identifying the critical sphingomyeli-
nase involved in ceramide formation (for example, acidic lipid synthesis is blocked by inhibition of a precursor
such as glucosylceramide. Support for this approach hasvs. neutral sphingomyelinase), determining the cellular
site for ceramide accumulation, defining the critical ef- been reported using a form of “experimental epistasis.”
By crossing knockout mice with the Sandhoff phenotypefectors of ceramide action, and demonstrating that sphin-
gomyelin hydrolysis and ceramide accumulation occur (due to GM2 accumulation) with those defective in Gal-
NAc transferase, Liu et al were able to prolong lifein a kinetically consistent manner.
Thus, both neutral and acidic sphingomyelinases have and postpone the neurological phenotype in the double
homozygous-affected offspring [161]. Support for sub-been implicated in cell death pathways [153, 154]. Cera-
mides formed secondary to exogenous sphingomyelinase strate depletion has also been reported for mouse models
of Tay-Sachs [162] and Sandhoff disease [163] using N-(presumably in the outer membrane leaflet), within
acidic cellular compartments, and via activation of a neu- butyldeoxynojirimycin, a relatively inactive inhibitor of
the cerebroside synthase. In these studies, mice weretral sphingomyelinase (presumably within the inner
membrane leaflet) have been implicated in the cell death treated with between 1.2 and 4.8 g/kg/day orally with
the inhibitor. The mice exhibited some prolongation ofresponse. Ceramide has been shown to activate effector
life and reversal of the accumulation of ganglioside[155] and executioner caspases [156]. Effector caspase
within their brains. Given the high dose of drug requiredactivation, however, may only result from the exposure
and the secondary toxicities of N-butyldeoxynojirimycin,of cells to short-chain ceramides. Finally, apoptotic stim-
the development of more active and less toxic inhibitorsuli have been associated both with very rapid and slowly
is required. Nevertheless, N-butyldeoxynojirimycin isrising ceramide levels. Perhaps when the role of ceramide
currently under evaluation in phase I and phase II trialsin the cell death response is fully delineated will more
for the treatment of Gaucher and Fabry diseases. At thefundamental questions regarding sphingolipid signaling
time of submission, the results of these trials had yet tobe answered.
be reported.
In vitro support for the treatment of Fabry disease is
SPHINGOLIPIDS AND THE KIDNEY based on the ability of two different PDMP homologues
With the discovery of new insights into sphingolipid to deplete Gb3 levels in lymphoblasts from a patient
biochemistry, cellular function, and pharmacology, in- with Fabry disease [164]. Concentrations as low as 10
vestigators have begun to consider what role sphingoli- nmol/L of either 49-hydroxyphenyl- or ethylenedioxy-
pids may play in renal physiology and pathophysiology. phenyl-2-decanoylamino-3-pyrrolidino-propanol result-
Gb3 levels accumulate in Anderson-Fabry disease, a ed in greater than 70% depletion of Gb3. By contrast
lysosomal storage disorder affecting the kidney. In this even 1000-fold higher concentrations of N-butyldeoxy-
X-linked disorder, affected males accumulate Gb3 and nojirimycin were unable to significantly lower Gb3 con-
globobiosylceramide in their kidneys, vascular, hearts, tent. Preliminary in vivo studies using a-glactosidase A
and peripheral nerve secondary to a loss of a-galac- knockout mice suggest that renal, hepatic, and cardiac
tosidase A activity, resulting in renal failure, cardiovas- Gb3 levels can be significantly lowered with prolonged
cular disease, and neuropathy. At least 30,000 individuals treatment with the ethylenedioxy P4 homologue.
are believed to suffer from this sphingolipidosis world- The verocytotoxin elaborated by pathogenic strains of
wide and 6000 within the United States [157]. However, Escherichia coli (O157:H7) associated with hemolytic
fewer than 100 patients are reported in the U.S. Renal uremic syndrome and hemorrhagic colitis binds to globo-
Data System to suffer end-stage renal disease as a result triaosylceramide. The epidemiological basis for hemo-
of Fabry disease. This disparity suggests that many pa- lytic uremic syndrome was established by Karmali et al
tients go undiagnosed. [165]. Gb3 is expressed on platelets; however, verotoxin
Gaucher disease, caused by a defect in b-glucosidase, is does not affect platelet aggregation. It is therefore the
currently treated with enzyme replacement therapy using cellular distribution of Gb3 within kidney and endothe-
lium of this glycosphingolipid receptor that correlatesmannose-terminated recombinant glucosidase [158]. A
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best with the pathophysiology of this disorder [166]. In ceramide in mediating renal injury is established, this
will provide important and obvious strategic approachessupport of this view is the observation that adult glomer-
uli poorly express Gb3, whereas Gb3 is highly expressed to intervention.
in the glomeruli of pediatric patients.
Hemolytic uremic syndrome is also prevalent in the
CONCLUDING THOUGHTSolder population, and yet glomeruli from normal older
Recent studies in the biochemistry and cellular biologypatients are verotoxin receptor negative. This may be
of sphingolipids have provided several potentially excit-explained by the observation that Gb3 levels can be
ing opportunities for providing new insights into normalinduced in response to multiple cytokines (particularly
and aberrant renal function. In many cases, there existsTNF, IL-1b, and lipopolysaccharide), suggesting a role
substantial evidence for a critical role of the unique lip-for glycolipids in the mediation of inflammatory re-
ids, such as receptors for bacterial toxin binding andsponses [167]. Gb3 can also be induced by viral infection
ligands for the Edg family of receptors. In other cases,such as with Epstein-Barr virus and HIV. It is a Burkitt
debate persists, and further work is required to establishlymphoma-associated antigen [168]. It is thus possible
proof of concept. Such proof will undoubtedly progressthat viral prodromes may render adult patients suscepti-
as additional enzymes in the metabolic pathways ofble to hemolytic uremic syndromes. Such a syndrome
sphingolipids are sequenced and characterized, as extra-has been reported for HIV [169].
cellular and intracellular targets of sphingolipid messen-If sphingosine-1-phosphate is produced and released
gers are unequivocally identified, and as new inhibitorsfrom activated platelets, then one might speculate that
of these enzymes and glycolipid receptors become avail-thrombotic disorders such as hemolytic uremic syndrome
able.may be mediated in part by sphingosine-1-phosphate
I have attempted to provide a balanced and criticalactivity. Sphingosine-1-phosphate stimulates mesangial
appraisal of the current status of sphingolipid biochemistrycell proliferation. Additionally, the Edg-1 and Edg-3 re-
and function. In many cases, the importance of sphingo-ceptors can be detected in developing mouse kidney
lipids is well established and unequivocal. In other cases,(abstract; Arend et al, J Am Soc Nephrol (Suppl)
although many proposed functions for sphingolipids are10:466A, 1999). Given the ability of sphingosine-1-phos-
very exciting in their implications in cell biology andphate to stimulate smooth muscle contraction, one might
pathophysiology, they remain unproven since they arespeculate that this lipid may mediate much of the renal
fundamentally descriptive. The potential role of sphin-pathology and hypertension observed in this syndrome.
golipids in protein sorting through lipid rafts, as media-Conversely, ceramide has been implicated as a pot-
tors of injury and repair and as receptors for pathogens,ential mediator of vascular relaxation. Cell-permeant
provides fertile ground for work by the renal investiga-ceramides have been demonstrated to attenuate agonist-
tive community. Classic models of renal function andstimulated vasoconstriction [170]. One potential mecha-
disease not only provide particularly useful opportunitiesnism for this effect may be the induction of endothelial
for clarifying the role of sphingolipids in the kidney andnitric oxide synthase (eNOS) by ceramide. Exogenous
vasculature, but also provide the opportunity to establishceramides have been reported to increase NO synthase
fundamentally and unequivocally a role for sphingolipidsactivity as well as the translocation of eNOS from the
endothelial membrane to intracellular sites. Bradykinin, in these vital processes.
a known inducer of eNOS, also raises cell ceramide levels
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